First results from RECOVER-AUTONOMIC clinical trials to be shared at upcoming conference

Results from the RECOVER-AUTONOMIC Moderate POTS (Ivabradine) clinical trial will be presented at a Late-Breaking Clinical Trials Session of the American College of Cardiology (ACC) Annual Conference on March 28, 2026. This session, Featured Clinical Research Session 201, will start at 12:00 pm CT (1:00 pm ET) and is only open to those registered for the conference. After the session, a public announcement about the results will be posted on the RECOVER website.

RECOVER-AUTONOMIC Moderate POTS (Ivabradine) is one of 2 RECOVER clinical trials testing possible treatments in adults who have postural orthostatic tachycardia syndrome (POTS) as part of their Long COVID symptoms. An autonomic nervous system disorder, POTS is characterized by unexpectedly fast heart rate (without a significant drop in blood pressure) that occurs within 10 minutes of standing up from sitting or lying down. POTS symptoms can also include dizziness, fainting, fatigue, headaches, blurred vision, pain, weakness in the legs, or a combination of these symptoms, which can make it challenging to manage everyday responsibilities.

The trial tested whether ivabradine—an oral medication that lowers heart rate and is used to treat people who have chronic heart failure with an elevated heart rate—may also help to manage POTS. People participating in the trial were randomly assigned to receive either ivabradine or a placebo (an inactive pill that is designed to look like the drug but does not have the drug’s effect). Participants were also assigned to receive either coordinated care or usual care for 3 months. Coordinated nondrug care includes regular check-ins with a care coordinator, as well as specific recommendations for diet and lifestyle changes.

RECOVER-AUTONOMIC Moderate POTS (Ivabradine) completed data collection in late 2025. Read about the design of the RECOVER-AUTONOMIC clinical trials, recently published in the American Heart Journal.